PORTA SOPRANA – FRIDAY 6 SEPTEMBER
17.30
Recombinant, patient-derived FVIII-neutralising antibodies: a platform for research, product testing, and ex vivo modelling of haemophilia A
C. Coxon (UK)
VIEW ePOSTER
17.40
Use of chromogenic Factor VIII activity determination in Haemophilia A plasma of patients under emicizumab treatment
N. Binder (Austria)
VIEW ePOSTER
17.50
Performance evaluation of a new fully automated thrombin generation instrument for the measurement of TGA in Haemophilia samples
N. Binder (Austria)
VIEW ePOSTER
18.00
ADAMTS13 Inhibitor Assessment with the HemosIL AcuStar ADAMTS13 Activity Assay
C. Valsecchi (Italy)
VIEW ePOSTER
18.10
Exploration and treatment strategies for gastrointestinal bleeding in Von Willebrand Disease over a 3-year period: a french-nationwide retrospective survey
A. Rauch (France)
VIEW ePOSTER
PORTA SOPRANA – SATURDAY 7 SEPTEMBER
18.30
Thrombin and plasmin generation in patients with plasminogen or plasminogen activator inhibitor type 1 deficiency
J.L. Saes (The Netherlands)
VIEW ePOSTER
18.40
Quantification of VWF propeptide release before and after desmopressin in von Willebrand disease and hemophilia A
L. Bukkems (The Netherlands)
VIEW ePOSTER
18.50
In vitro and in vivo modulation of von Willebrand factor gene mutations with dominant-negative effect
C. Casari (Italy)
VIEW ePOSTER
19.00
Long-term neuropsychological sequelae, emotional wellbeing and quality of life in patients with acquired thrombotic thrombocytopenic purpura
I. Mancini (Italy)
VIEW ePOSTER
19.10
Non-specific non-antiphospholipid inhibitor in a 26-years-old woman: a case report with few answers and many questions
N. Ciavarella (Italy)
VIEW ePOSTER